Zentalis Pharmaceuticals, Inc. (ZNTL) News
Track canonical SquawkNews coverage tagged to ZNTL, Zentalis Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL ) received a bullish initiation from William Blair, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib. William Blair analys
LIVE | Sep 16, 2026, 05:38 PM UTC
L
ZNTL: Azenosertib nears pivotal data in ovarian cancer, with FDA backing and robust financial runway
Azenosertib is advancing in late-stage trials for platinum-resistant ovarian cancer, with strong FDA support and a differentiated safety profile. Expansion into earlier lines and other tumor types is under evaluation, wh
REGULATION | Sep 14, 2026, 08:49 PM UTC
L
ZNTL: Azenosertib advances toward accelerated approval in ovarian cancer with robust clinical and regulatory momentum
Azenosertib is advancing through late-stage trials for platinum-resistant ovarian cancer, showing strong efficacy and safety in Cyclin E1-positive patients. Regulatory feedback supports the accelerated approval pathway,
NEWS | Sep 14, 2026, 07:44 PM UTC
M
ZNTL azenosertib advances in platinum-resistant ovarian cancer
Azenosertib’s key clinical trials in platinum-resistant ovarian cancer are progressing, supported by robust safety oversight and a validated biomarker strategy.
EQUITY | Sep 08, 2026, 09:57 PM UTC
M
ZNTL advances pivotal Azenosertib ovarian cancer trials with FDA support
Azenosertib is advancing through pivotal trials for platinum-resistant ovarian cancer, citing a robust safety profile and a validated biomarker strategy. The company says FDA alignment is strong and highlights a differen
REGULATION | Sep 08, 2026, 09:27 PM UTC
L
ZNTL - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
ZNTL - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:08 PM UTC
L
Zentalis announces inducement grants under Nasdaq Rule 5635(c)(4)
Zentalis Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 09:16 PM UTC
L
Zentalis Pharmaceuticals announces Nasdaq inducement grants under Rule 5635(c)(4)
Zentalis Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 09:15 PM UTC
L
ZNTL rises premarket as Walters Group buys 4.33M shares
ZNTL is up 4.71% in pre-market after 10% owner Walters Group filed an insider buy of 4.33M shares for $15.17M, taking its holdings to 17.84M shares.
EQUITY | Aug 20, 2026, 12:55 PM UTC
L
Zentalis Pharmaceuticals closes underwritten public offering, full option exercise
Zentalis Pharmaceuticals (ZNTL) announces the closing of its underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares.
EQUITY | Aug 17, 2026, 08:01 PM UTC
L
Zentalis Pharmaceuticals (ZNTL) prices underwritten public offering
Zentalis Pharmaceuticals (ZNTL) announces the pricing of an underwritten public offering, as stated in the news release headline and body.
MNA | Aug 14, 2026, 02:23 AM UTC
M
Zentalis Pharmaceuticals proposes underwritten public offering of shares
Zentalis Pharmaceuticals (ZNTL) announces a proposed underwritten public offering, with no further terms, pricing, or size provided in the feed.
MNA | Aug 13, 2026, 08:02 PM UTC
L
ZNTL new Buy W/ $11 PT @ Rodman
ZNTL new Buy W/ $11 PT @ Rodman
EQUITY | Jul 23, 2026, 12:03 PM UTC
L
ZNTL Initiated Buy W/$11.00 PT at Rodman & Renshaw
ZNTL Initiated Buy W/$11.00 PT at Rodman & Renshaw
EQUITY | Jul 23, 2026, 11:55 AM UTC
H
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Nasdaq Composite falling around 400 points on Friday. Shares of ManpowerGroup Inc (NYSE: MAN ) rose sharply after the company reported upbeat second-quarter results and issued third-quart
EARNINGS | Jul 17, 2026, 02:09 PM UTC
L
early moves among today's upgrades MMM +0.8%, ABR +0.5%, ECL +0.4%, EMR +0.3%, AAPL +0.0%, ASTS -0.4%, FERG -0.9%, ECHO -1.7% early moves am
early moves among today's upgrades MMM +0.8%, ABR +0.5%, ECL +0.4%, EMR +0.3%, AAPL +0.0%, ASTS -0.4%, FERG -0.9%, ECHO -1.7% early moves among today's positive initiations PXED +2.0%, MCO +0.0%, OMDA -0.5%, MSCI -1.0%,
EQUITY | Jul 17, 2026, 11:59 AM UTC
L
ZNTL Initiated Outperform W/$8.00 PT at Mizuho
ZNTL Initiated Outperform W/$8.00 PT at Mizuho
EQUITY | Jul 17, 2026, 11:56 AM UTC
L
ZNTL new Outperform W/ $8 PT @ Mizuho
ZNTL new Outperform W/ $8 PT @ Mizuho
EQUITY | Jul 17, 2026, 11:08 AM UTC